The global diabetic retinopathy market size is expected to reach USD 13.77 billion by 2030, registering a CAGR of 6.4% from 2023 to 2030, according to a new report by Grand View Research, Inc. The incidence rate of diabetes has been increasing dramatically. According to the International Diabetes Federation, in 2021 there were about 537 million diabetic cases, which is projected to rise to 643 million by 2030 and 783 million by 2045. Diabetes is among the leading cause of blindness in people. Blindness is caused due to leaking or rupturing of retinal blood vessels, which may be permanent or temporary in nature depending on the disease stage. Studies suggest that in 2020 the number of diabetic retinopathy cases were about 103.12 million; the cases are expected to reach 160.5 million by 2045.
Diabetic Retinopathy Market Report Highlights
- The non-proliferative diabetic retinopathy segment accounted for the largest revenue share of 70.5% in 2022. The presence of a large number of patients within the bracket of fewer than 10 years of diabetic history contributed to the large size of this segment
- The anti-VEGF drugs accounted for the largest revenue share of 92.8% in 2022 owing to their efficiency and efficacy in the treatment of diabetic retinopathy. The high applicability of these drugs in the treatment and early diagnosis of mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth
- In Asia Pacific, the market is expected to witness the highest CAGR over the forecast period. The large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market
Gain deeper insights on the market and receive your free copy with TOC now @: Diabetic Retinopathy Market Report
Diabetic retinopathy is a serious eye condition that occurs as a complication of diabetes. It specifically affects the retina, which is the light-sensitive tissue lining the back of the eye. High blood sugar levels over an extended period of time can damage the small blood vessels within the retina, leading to various changes and abnormalities. There are two main types of diabetic retinopathy: non-proliferative and proliferative. Non-proliferative diabetic retinopathy is the early stage of the condition, where the blood vessels in the retina leak fluid and blood, causing swelling and the formation of small deposits called exudates. This stage may not exhibit noticeable symptoms, but regular eye examinations can detect these changes. Proliferative diabetic retinopathy is the advanced stage of the disease. In this stage, the damaged blood vessels of the retina prompt the growth of new, abnormal blood vessels. These new vessels are fragile and prone to bleeding, which can lead to the formation of scar tissue. As the disease progresses, the scar tissue can contract and pull on the retina, causing it to detach and resulting in severe vision loss or blindness if not treated promptly. Diabetic retinopathy commonly affects both eyes, and individuals with diabetes are at a higher risk of developing this condition. Factors that contribute to its development include the duration of diabetes, poorly controlled blood sugar levels, high blood pressure, high cholesterol, and pregnancy. Treatment options depend on the stage of the disease and may include laser therapy to seal leaking blood vessels, injections of medications to reduce abnormal blood vessel growth, and surgery in advanced cases. Additionally, effective management of diabetes through proper blood sugar control, blood pressure management, and healthy lifestyle choices can help prevent or slow the progression of diabetic retinopathy.
The Diabetic Retinopathy market has witnessed advancements in diagnostic technologies, such as retinal imaging and optical coherence tomography (OCT). These technologies enable earlier and more accurate detection of retinal changes associated with diabetic retinopathy, facilitating timely intervention and treatment. Research and development efforts have focused on developing new pharmacological treatments for diabetic retinopathy. Anti-vascular endothelial growth factor (VEGF) drugs, such as ranibizumab and aflibercept, have shown efficacy in reducing abnormal blood vessel growth and improving vision in patients with diabetic macular edema, a complication of diabetic retinopathy. AI and machine learning technologies are being increasingly explored in the field of diabetic retinopathy. These technologies can analyze retinal images and OCT scans to detect and classify diabetic retinopathy, aiding in early diagnosis and monitoring of the disease. AI-based screening tools have the potential to improve access to diabetic retinopathy screening in underserved areas and streamline the detection process. Telemedicine and remote monitoring platforms have gained prominence, particularly during the COVID-19 pandemic. These platforms allow healthcare professionals to remotely assess and monitor patients with diabetic retinopathy, reducing the need for in-person visits and improving patient convenience and access to care. There is growing interest in personalized medicine approaches for diabetic retinopathy. Genetic profiling and biomarker identification may help predict an individual’s risk for developing diabetic retinopathy or its progression, enabling targeted interventions and treatments based on the patient’s specific profile. Various stakeholders, including pharmaceutical companies, technology providers, research institutions, and healthcare organizations, are collaborating to advance the field of diabetic retinopathy. Collaborative efforts aim to improve understanding, develop innovative solutions, and enhance patient outcomes through a multidisciplinary approach.
Rising patient awareness levels and increasing healthcare expenditure are also among the factors which are likely to propel market growth. Moreover, the increasing geriatric population in both developed and developing nations is expected to propel the market over the forecast period. According to the Population Reference Bureau report titled “Aging in the United States”, the number of people in the U.S. aged 65 years and over was projected to increase from around 46 million in 2016 to over 98 million by 2060. Early detection and treatment guidelines for diabetic retinopathy had significantly reduced due to the COVID-19 pandemic-related constraints. When compared to 2019, intravitreal injections for diabetic retinopathy had decreased significantly globally throughout the pandemic, ranging from around 30 to over 100 percent reduction. However, now that the lockdown restrictions have been removed, the market is expected to grow at a significant rate.
Diabetic Retinopathy Market Insights By Region
North America dominated the market and accounted for the largest revenue share. The presence of sophisticated healthcare infrastructure, favorable government initiatives pertaining to drug development, and the presence of high patient and practitioner awareness levels are some of the drivers of this market. Some of the major drivers are high healthcare expenditure, increase in patient awareness about diabetes, presence of well-established healthcare infrastructure, and favorable reimbursement framework. The Asia Pacific market is expected to witness a lucrative growth, due to the presence of high unmet medical needs, coupled with rapidly rising patient awareness regarding effective diagnostic procedures for diabetes and rising healthcare expenditures in the emerging economies of India and China. Latin America and Middle East regions are also anticipated to witness lucrative growth over the forecast period.
Competitive Analysis By Major Players
Major players are focusing on collaborations, partnerships, mergers, and other strategic activities to improve their market position. Market leaders face increased competition from new drug launches and new management treatment approval from regulatory bodies, making it difficult for them to sustain themselves in the ever-changing market. However, heavy investments in R&D conducted by market leaders are said to boost market growth. Some of the prominent players in the diabetic retinopathy market are:
- Bayer AG
- Allergan plc
- Novartis AG
- Oxurion NV
- Sirnaomics Inc.
- Genentech
For More Details or Sample Copy please visit link @: https://www.grandviewresearch.com/industry-analysis/diabetic-retinopathy-market/request/rs1
Grand View Research has segmented the global diabetic retinopathy market based on type, management, and region.
Research Methodology
We employ a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecasts possible. We utilize a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our market estimates and forecasts are derived through simulation models. A unique model is created and customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously.
For Customized reports or Special Pricing please visit @: https://www.grandviewresearch.com/checkout/select-license/diabetic-retinopathy-market
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S. based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Contact:
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll-Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com